Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs target ASCT2, a transporter abundant in…
Continue Reading
News Source: medicalxpress.com
Leave a Reply